Filipinos mull class suit over dengue vaccine fiasco
French drug-maker's admission that vaccine could worsen symptoms in some cases sparks health scare

Members of the Gabriela women's group protest over what they call the premature use on Filipino children of a dengue vaccine. (Photo by Jimmy Domingo)
December 6, 2017
Parents of 700,000 children immunized under a government dengue vaccine campaign are mulling whether to file a class suit against French drug-maker Sanofi Pasteur for exposing them to health risks.
Parent representative Ernesto Francisco, Jr. on Dec. 5 said a class suit against the pharmaceutical firm would ensure funds for medical expenses if children suffer adverse effects of the dengue vaccine Dengvaxia.
The Philippine government last week suspended the US$68-million dengue immunization drive after Sanofi disclosed its vaccine could, in some cases, worsen the disease.
"We are stopping the program until we can get recommendations from the WHO [World Health Organization]," Health Secretary Francisco Duque III said Dec. 1.
The Food and Drug Administration also ordered the drug-maker to remove the vaccine from the local market.
Philippine clergy, meanwhile, used the controversy to step up their warnings against the use of artificial contraceptives.
Dengue fever is a mosquito-borne viral infection that can cause severe flu-like symptoms, which can prove deadly in some cases.
The government rolled out the vaccine before the WHO published a position paper on its use and risks, according to the agency's Philippine office.
The administration of former Philippine president Benigno Aquino gave Dengvaxia the green light in 2015.
It launched the vaccination drive for public elementary school students at the start of 2016, despite warnings of premature use and a lack of transparency in studies on its effects.
The WHO had asked the government to consider using the vaccine only "in areas where at least 70% of the community had already been exposed to the virus," and only for people aged nine years old and over.
In April 2016, WHO acknowledged the government's pilot areas met the exposure criteria.
It published its position paper more than six months after the government approved the vaccine.
However, "The WHO position paper did not include a recommendation to countries to introduce the dengue vaccine into their national immunization programs," the world health body's country office said in a statement.
Sanofi last month stunned the immunization market with the disclosure that its vaccine could increase risks of "severe dengue" in people who have not contracted the disease before.
A statement by the company on Dec. 5 said the complications would not be fatal.
Related Reports
LATEST

-
Vandals 'sought to divide' indigenous communities in Odisha
Fact-finding team believes attacks on a temple and two churches aimed to stoke tensions in Indian state
-
Filipino youths get grounding on social media use
Palo Archdiocese stresses need to use technology responsibly and for propagating Catholic Church teachings
-
Catholic church seized as China ramps up Henan crackdown
Local government accused of trampling on religious policies with 'brutal enforcement' of revised regulations
-
Philippines orders Australian missionary nun to leave
Authorities revoke Sister Patricia Fox's visa, give her 30 days to get out the country
-
Former Islamic cleric could be Malaysia's kingmaker
Unlikely election alliance between PAS and UMNO could result in the country taking a stronger Islamic direction
Support Our Journalism
Quick Donate
